Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2009 1
2012 1
2013 1
2014 3
2015 3
2016 7
2017 7
2018 5
2019 15
2020 17
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

55 results
Results by year
Filters applied: . Clear all
Page 1
High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment.
Solimando AG, Da Vià MC, Cicco S, Leone P, Di Lernia G, Giannico D, Desantis V, Frassanito MA, Morizio A, Delgado Tascon J, Melaccio A, Saltarella I, Ranieri G, Ria R, Rasche L, Kortüm KM, Beilhack A, Racanelli V, Vacca A, Einsele H. Solimando AG, et al. Among authors: rasche l. J Clin Med. 2019 Jul 9;8(7):997. doi: 10.3390/jcm8070997. J Clin Med. 2019. PMID: 31323969 Free PMC article. Review.
A review on tumor heterogeneity and evolution in multiple myeloma: pathological, radiological, molecular genetics, and clinical integration.
Schürch CM, Rasche L, Frauenfeld L, Weinhold N, Fend F. Schürch CM, et al. Among authors: rasche l. Virchows Arch. 2020 Mar;476(3):337-351. doi: 10.1007/s00428-019-02725-3. Epub 2019 Dec 17. Virchows Arch. 2020. PMID: 31848687 Review.
On-target restoration of a split T cell-engaging antibody for precision immunotherapy.
Banaszek A, Bumm TGP, Nowotny B, Geis M, Jacob K, Wölfl M, Trebing J, Kucka K, Kouhestani D, Gogishvili T, Krenz B, Lutz J, Rasche L, Hönemann D, Neuweiler H, Heiby JC, Bargou RC, Wajant H, Einsele H, Riethmüller G, Stuhler G. Banaszek A, et al. Among authors: rasche l. Nat Commun. 2019 Nov 26;10(1):5387. doi: 10.1038/s41467-019-13196-0. Nat Commun. 2019. PMID: 31772172 Free PMC article.
What is the future of immunotherapy in multiple myeloma?
Rasche L, Hudecek M, Einsele H. Rasche L, et al. Blood. 2020 Nov 26;136(22):2491-2497. doi: 10.1182/blood.2019004176. Blood. 2020. PMID: 32735639
Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome.
Mohan M, Weinhold N, Schinke C, Thanedrarajan S, Rasche L, Sawyer JR, Tian E, van Rhee F, Zangari M. Mohan M, et al. Among authors: rasche l. Br J Haematol. 2020 Apr;189(1):67-71. doi: 10.1111/bjh.16292. Epub 2019 Dec 9. Br J Haematol. 2020. PMID: 31820442
Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma.
Weinhold N, Ashby C, Rasche L, Chavan SS, Stein C, Stephens OW, Tytarenko R, Bauer MA, Meissner T, Deshpande S, Patel PH, Buzder T, Molnar G, Peterson EA, van Rhee F, Zangari M, Thanendrarajan S, Schinke C, Tian E, Epstein J, Barlogie B, Davies FE, Heuck CJ, Walker BA, Morgan GJ. Weinhold N, et al. Among authors: rasche l. Blood. 2016 Sep 29;128(13):1735-44. doi: 10.1182/blood-2016-06-723007. Epub 2016 Aug 11. Blood. 2016. PMID: 27516441 Free PMC article.
Carfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma with Extramedullary Disease.
Zhou X, Flüchter P, Nickel K, Meckel K, Messerschmidt J, Böckle D, Knorz S, Steinhardt MJ, Krummenast F, Danhof S, Einsele H, Kortüm KM, Rasche L. Zhou X, et al. Among authors: rasche l. Cancers (Basel). 2020 Apr 23;12(4):1035. doi: 10.3390/cancers12041035. Cancers (Basel). 2020. PMID: 32340174 Free PMC article.
Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores the angiogenic homeostasis and suppresses tumor progression.
Solimando AG, Da Vià MC, Leone P, Borrelli P, Croci GA, Tabares P, Brandl A, Di Lernia G, Bianchi FP, Tafuri S, Steinbrunn T, Balduini A, Melaccio A, De Summa S, Argentiero A, Rauert-Wunderlich H, Frassanito MA, Ditonno P, Henke E, Klapper W, Ria R, Terragna C, Rasche L, Rosenwald A, Kortüm KM, Cavo M, Ribatti D, Racanelli V, Einsele H, Vacca A, Beilhack A. Solimando AG, et al. Among authors: rasche l. Haematologica. 2020 Apr 30:haematol.2019.239913. doi: 10.3324/haematol.2019.239913. Online ahead of print. Haematologica. 2020. PMID: 32354870 Free article.
Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients.
Jones JR, Weinhold N, Ashby C, Walker BA, Wardell C, Pawlyn C, Rasche L, Melchor L, Cairns DA, Gregory WM, Johnson D, Begum DB, Ellis S, Sherborne AL, Cook G, Kaiser MF, Drayson MT, Owen RG, Jackson GH, Davies FE, Greaves M, Morgan GJ; NCRI Haemato-Oncology CSG. Jones JR, et al. Among authors: rasche l. Haematologica. 2019 Jul;104(7):1440-1450. doi: 10.3324/haematol.2018.202200. Epub 2019 Feb 7. Haematologica. 2019. PMID: 30733268 Free PMC article. Clinical Trial.
CIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF-MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System Involvement.
Da Vià MC, Solimando AG, Garitano-Trojaola A, Barrio S, Munawar U, Strifler S, Haertle L, Rhodes N, Teufel E, Vogt C, Lapa C, Beilhack A, Rasche L, Einsele H, Kortüm KM. Da Vià MC, et al. Among authors: rasche l. Oncologist. 2020 Feb;25(2):112-118. doi: 10.1634/theoncologist.2019-0356. Epub 2019 Oct 18. Oncologist. 2020. PMID: 32043788 Free PMC article.
55 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback